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Abstract In the last 10 years, the area of ELISA and
protein-chip technology has developed and enthusiasti-
cally applied to an enormous variety of biological
questions. However, the degree of stringency required
in data analysis appears to have been underestimated. As
a result, there are numerous published findings that are
of questionable quality, requiring further confirmation
and/or validation. In the course of feasibility and
validation studies a number of key issues in research,
development and clinical trial studies must be outlined,
including those associated with laboratory design, ana-
lytical validation strategies, analytical completeness and
data managements. The scope of the following review
should provide assistance for defining key parameters in
assay evaluation and validation in research and clinical
trial projects in prospective medicine.
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Introduction
ELISA multiplex protein-chip technology and imaging
techniques, are powerful means of rating a lot of analytical
data in the frame of a single experiment. This analytical
information is used to understand the nuance of the protein
expression profile of a biological system, and in many cases it
is the basis of comparison of two or more sample sets. Yet the
technical difficulty and high cost of data production,
associated with highly time-consuming data analysis, has
contributed to a position where a poor laboratory workflow is
common. Many experiments have a low number of analytical
and/or biological replicates, and user often assume that
multiple estimates rated by a single experiment provide a
substitute for experimental replicas. The reproducibility of
techniques used, as assayed by regression analysis, co-
efficient of variation or other variance estimation techniques
[1] is typically not reported. Power analysis, which can be
used to infer the number of samples that should be analysed
to discover a statistically significant result [1–3], are rarely
undertaken. Weak design of experiments, particularly in a
field where technical challenges remain in the production of
high quality data, can make it difficult or impossible to
determine if differences reported between two or more
sample sets are likely to reflect variation in a biological
system or are solely analytically derived.
The complexity of an analytical validation should
reflect the aim of the analysis and thus has to be in
accordance with the intended use. In other words, a
validation of a method for a research project has to be
scientifically defendable whereas a method designed for
tracking critical parameter during development of a
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manufacturing process or ensuring product quality
parameters within specified limits has to be validated in
accordance with cGMP standard [4]. Therefore, valida-
tion can be seen as the process of demonstrating that an
assay is suitable for its intended use [4].
The scope of the following proposals and examples
should provide assistance for defining good practice for
assay performance in research and early phase clinical
trial projects. The process by which a specific bioana-
lytical method is developed, evaluated and finally
validated for it’s intended use can be divided into (1)
reference standard preparation, (2) bioanalytical method
development and establishment of assay procedure, and
(3) application of the validated bioanalytical method for
routine analysis and release for the analytical run and/or
batch. Commercially available tests have not necessarily
undergone all of these steps. Asking the vendor for
additional data on assay development and evaluation may
significantly and easily improve the analysts knowledge about
assay properties.
For analysis of single compounds in complex matrices
like different human fluids, specificity (selectivity) is a
prerequisite for valid results. According to the ICH
Guideline Q2R, specificity is the ability to assess unequiv-
ocally the analyte in the presence of components which
may be expected to be present. Typically these might
include impurities, degradants, matrix, etc.
Furthermore, using test samples with known concentra-
tion or generating samples with spiked standard substance
allows to describe the difference between the value
obtained by the test method and the theoretical value which
is defined as the assay accuracy.
For ELISA-, and protein-chip-assays, but also for other
bioassays, it is strongly recommended that reference
material is identical to the sample material and reference
matrix and sample matrix have identical compounds or at
least behave similar. If possible, an adequate number of
control samples should be prepared and stably stored early
during assay development. If tested with each assay run,
this control provides great advantage by monitoring the
assay performance. It is a valuable tool to track assay
performance parameters like the assay variability over time.
The random assay variability gives a first, rough estimate
on the QL (Quantitation Limit) which is the lowest level
of analyte that can be measured with sufficient precision
and accuracy. For this purpose 6 times the standard
deviation is a rough estimate for the QL which should be
analytically proved. All values below the QL should be
reported as “below QL”, or below the concentration
value corresponding to QL. No scientific conclusion
should be taken from comparing of results that are below
the QL. Assay variability should be investigated and
reported as the assay precision. The precision of an
analytical method expresses the closeness of agreement
between a series of measurements obtained from multiple
sampling of same homogeneous sample and may be
reported as the coefficient of variation CV%. Taking into
consideration that most studies are performed on more
than 1 day, the effects of random events to the analytical
procedure may be tested to ensure comparable test results
between e.g. different test starts, different analysts,
different lots of antibodies or different equipment. The
interval between the upper and lower concentration of
analyte in the sample where the procedure has a suitable
level of precision and accuracy should be specified as the
range of the method.
Control samples are also important to define limits for
assay acceptance criteria. If the actual assay differs more
than 3 times the standard deviation from the historical
mean, it may be investigated if an analytical error has
occurred and if an error is identified, the assay may be
repeated without considering the initial results.
Monitoring of control samples make it possible to
identify a bias (difference) in the results over time or a
bias that appears suddenly between two assays. The latter
might be caused by the change of a reagent, equipment or
analyst without performing material bridging study or
sufficient training of the new analyst. There are many
arguments why such a bias should be avoided within a
study. But if it happens the back calculation of sample
results with the tracked bias of the control samples may
save the study. This is the case if the analyte is instable and
samples can not be stored and therefore the testing can not
be repeated.
Investigation of change of sensitivity across a plate is
important as usually multiple wells of a multiwell-plate are
used for the testing procedure. Therefore the uniformity of
the assay performance over the plate should be investigated
by a single dose that is used across the entire plate.
Therefore, a sample concentration within the reference
standard curve should be chosen that represents the greatest
sensitivity to change in dose. The pipetting scheme and the
output detection of each individual well should be
processed in the same way as planned for the test. The
results may be shown in a 3D Uniformity trial plot [5], see
Fig. 1.
If deviations from uniformity are detected, the plate
layout can be designed to minimise plate effects. In the
shown example, the right side of the plate shows reduced
sensitivity compared to the left side. In such a cases the
cause should be investigated. One possible cause may be
the time limitation of a luminescent readout. In such a case
the shortening of the reading time for each well increases
the assay variability but reduces the bias across the plate.
Furthermore an appropriate plate design that spreads the
duplicates across the plate may be also useful to minimise
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the bias of samples located to different sites of the plate [5].
If a bias occurs, a suitable template design minimises the
bias, mainly by transforming the bias into assay variability.
Assay variability can be handled statistically e.g. by an
increased number of replicates that are spread over the plate.
Assay variability, biological variation of the samples and
small differences in sample pre-treatment may lead to
variability of the assay results. To consider this fact, it is
suggested not only to report the mean of the individual
replicates as result but also report the consensus interval (e.
g. CI 95%) or the standard deviation for improved
interpretation of the data. If the assay results are not
normally distributed, the geometric mean of the replicates,
rather than the arithmetic mean should be reported [6].
Assay performance parameters are given in Table 1.
Differential display and biomarker discovery
ELISA, multiplex assay and protein-chip techniques are
widely used for the determination of differentially expressed
proteins, including biomarkers. Multi screening techniques
can be used in a hypothesis-independent manner (change from
hypothesis to discovery driven research), making them
attractive for this purpose. Whilst statistical tests are increas-
ingly applied to expression data, proteins are frequently
published as differentially expressed on the basis of a two-
fold or greater expression difference. Such conclusions ignore
the analytical and biological variation inherent to any
laboratory and the samples under study. It is also not
infrequent to see proteins described as differentially expressed
from the use of univariate statistical tests (e.g. Student’s t-test),
but where the normal distribution of the data has been
assumed but not tested. This is of great concern as
expression data are typically not normally distributed and
requires transformation before many statistical tests can be
applied [1, 3]. After appropriate statistical analysis, it may
come to pass that a two-fold expression difference is shown
to be significant for a particular protein. However, it is only
the detailed analysis of expression data, involving data
normalisation, appropriate transformation, determination of
the inherent variance and the use of suitable uni- and
multivariate statistical test, that this can be resolved.
Analytical incompleteness of multiplex protein
expression/determination analysis
Analytical incompleteness refers to a phenomenon where a
technique used for the analysis of a complex mixture of
peptides/proteins may only yield information for a fraction of
relevant peptides/proteins in any single analytical run. For
example, it has been observed that two replicate analysis of a
multiplex protein-chip experiment will produce two sets of
different expression profiling with ~65% overlap [7, 8].
Thirty-fife percent of the protein in the second analysis are
likely to be novel compared to the first. A third replicate
analysis is likely to yield a set of identification that has 80%
overlap with those from the first two analyses, but with 20%
new identification. Because of the differences in proteins seen
per run, it has been estimated that 10–12 analysis may be
necessary before a near complete of protein identities is rated
from a single complex sample [7, 8]. This phenomenon has a
substantial impact on the use of protein arrays for qualitative
biomarker discovery experiments, as the presence or absence
of a protein in a particular run may reflect analytical
incompleteness instead of true differences between samples.
Accordingly, the comprehensive comparison of two or
more proteome analysis by these approaches will require
great care and high numbers of replicates [9]. It should
finally be noted that analytical completeness is also
inherent to the technique, where it can arise from
inconsistent sample extraction and amplification, leading
to difference in the protein expression determined in
western blot (WB), ELISA etc. [10]. However the paradigm
of proteomics via affymetrix typically identifies proteins or
genes of interest only after statistical expression analysis,
making this a less pressing issue.
In the content of the above concerns, we recommend
initiate a process to develop a set of minimum guidelines
for the field of ELISA, and multi-protein-chip assay, which
could assist in the execution of protein determination
experiments and in the improving of the quality in the data.
Figure 2 demonstrates evaluation, validation and test
























Fig. 1 Example of a 3D uniformity plot of sensitivity across a plate.
Each well of a 96 well plate contains the same amount of analyte.
Please note the bias of the readout response from left to right. This
effect was caused by an instable readout signal and slow well scanning
row by row, starting at row 1 lane A, ending with row 12 lane F
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Recommended workflow: assay validation protocol
for immunoassays (ELISA and multiplex protein-chip
assay) proposed for prospective medicine
Prevalidation / evaluation
Order 2 kits from 2 different suppliers for the analyte-
specific assay which has to be validated. If necessary, get
additional aliquots of the lot-specific standard. If a WHO
standard preparation of the analyte studied is available,
order as well. Alternatively, get a large stock of a stable
preparation (lyophilised) of analyte from independent
suppliers.
a) Prepare a standard curve with the kit-standard spiked in
one human plasma and in horse plasma; run the spiked
plasma samples along with kit standards in duplicate on
one plate.
b) Run 25 different human plasma samples from different
donor in triplicates.
If the majority of data (>80%) fulfill a % CV criteria of
below 20% (data from a & b) and a constant spike recovery
(data from a—after accounting for endogenous level in
human plasma) above 50% over the concentration range
tested continue with the validation.
Validation
1. Depletion of endogenous analyte-level => assessment
of specificity of baseline levels
– If the analyte levels are in agreement with the
literature data skip immunodepletion and continue
with point 2.
– Take the capture antibody from the assay you want
to validate.
– Add the antibody to the 10 human plasma
samples from different donor at a concentration
of 20 μg/ml.
– Incubate the plasma samples with the antibody
overnight at +4°C on ice.
– Run the undepleted and depleted plasma samples in
triplicate.
– If the baseline levels can be depleted by two-third
or more continue with point 2.
– If the baseline levels can not be depleted by two-
third or more discard the assay.
2. Different human plasma => assessment of major matrix
effects
– Determine the analyte-level of 10 different
human plasma samples from different donor
(the results from the prevalidation can be taken
for selecting the plasma in order to cover a
maximum range).
– Spike the standard-protein in two different concen-
trations to the individual plasma (3× and 10× of the
mean endogenous level).
– Run this unspiked and spiked plasma samples in
triplicate.
– If the %CV are below 20% and the spike recovery
constant over the individual patient samples tested
and exceeds 50%, continue with point 3.
3. Variability and LLoQ
– Prepare a standard curve with the kit-standard
spiked in one human plasma and in horse plasma
identical to point 1. The human plasma with the
Table 1 Typical assay performance parameters addressed in assay validation to make the assay scientifically defendable
Assay performance
parameter
Outcome / benchmark Examples
Specificity Detection of the analyte. No detection of matrix components. No cross reactivity with other components that
are expected in the sample matrix.
Linearity If applicable, linear range of the standard curve R2>0,98 5 dilution points of the standard curve show a
linear dose response relation.
Range Sample concentration where linearity, accuracy and precision
are within the expected limits. The lowest valid concentration
of the range is the Quantitation Limit
Results from accuracy and precision can be used.
Accuracy 80–120% of spiked value Sample matrix spiked with 5 known concentrations
of standard.
Intermediate precision RSD% <25% 2 different analysts, 2 different days, 2 different
readout systems or batches of antibody
Robustness Investigation of assay sensitivity to possibly
occurring influences.
Incubation time and temperature, performance
of plate washing, equipment
The shown benchmarks represent an estimate for multiple types of immunological assays and strongly depends on the assay method and the
intended use
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lowest endogenous signal identified in the preva-
lidation should be used.
– Run this standard curve in duplicate/plate on two
different plates; this should be done independently
by two different operators on two different days
(the results of the prevalidation can be also
included in the validation).
– From this results assess precision and accuracy and
derive LLoQ (also mentioned as QL = Quantitation
Limit) is defined by the spike concentration where
the CV is below 20% and the recovery is still in a
constant range.
4. In-run controls
– From the 25 different human plasma samples
(prevalidation), define three with different concen-
trations (>3 fold difference between the con-
centrations) as assay controls; if the plasma
samples do not display analyte levels that
span an appropriate range the analyte has to
be spiked to one plasma in order to achieve
three different concentrations.
– Include four replicates of these three control
plasma samples per plate (from part 3 above) at
different positions on the plate to detect the
mean and the range of the controls out of 16
replicates.
– These controls have to be included in duplicate
on all assay plates where clinical samples are run
(so-called in-run controls); 5/6 of the in run-
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Fig. 2 A scheme of evaluation:
Typical assay performance
parameters addressed in assay
validation and test validation
processes for immunoassay,
taken modified from [11]. The
shown benchmarks represent an
estimate for multiple types of
immunological assay and
strongly depends on the assay
method and the intended use
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5. Assessment of independent standard
– An independent standard preparation of the
analyte (if available, WHO standard) should be
spiked at 5 different concentrations into horse
plasma and assessed in duplicate over the four
plates used in 3. Average and % CV should be
derived. Any new lot should be tested with
identical spikes and should only be released for
clinical sample analysis if independent standard
spikes are in agreement with the one determined
during validation.
Recommendation for data management
Laboratory workflow and data analysis for ELISA analysis
and multiplex-based experiments:
– The laboratory workflow must be provided and
must include details of the number of biological
and analytical replicates. Only one biological/
analytical replicate is not acceptable. For clinical
samples, it is highly desirable that a power
analysis predicting the appropriate sample size for
subsequent statistical analysis of the data is carried
out.
– For protein expression studies, summary statistics
(mean, standard deviation) must be provided and
results of statistical analysis must be shown. Reporting
fold differences alone is not acceptable. The report
must include the following: method of date normal-
isation, transformation, missing value handling, the
statistical tests used, the degrees of freedom and the
statistical package or programme used. Where biolog-
ically important differences in protein expression are
reported, confirmatory data (e.g. Western Blot (WB),
ELISA) are desirable.
– For biomarker discovery/validation studies, the
sensitivity and specificity, the positive predictive
value (PPV), negative predictive value (NPV),
likelihood ratio (LR) and odds ratio (OR) of the
biomarker(s) should be provided wherever possible.
It is desirable that receiver operator characteristic
(ROC) curves and areas under the curves are
given.
Protein identification and characterisation
– The method(s) used to measure the protein
expression data must be described.
– The name and version of the programme used for
database searching, the values of critical search
parameters must be provided.
– For experiments with large protein expression
data sets, estimates of false positive rates are
required (e.g. through searching randomised
or reversed sequence database). This informa-
tion should be provided as supplementary
material.
– When post translation modification (PTM) of
proteins are reported, the amino acids sequence
that matches the unique peptide sequence of a
particular isoform must be provided.
Bioinformatics
– Where a report describes an academic database or
software, it must be either freely accessible via the
internet, intranet or downloadable and the access
options must be provided. This also applies to
commercial software or databases.
Normalisation
– Default normalisation: Values below 0.01 were
set to 0.01. Each measurement must divided by
the 50.0th percentile of all measurements in that
sample. Each protein analyte must divide by the
median of its measurements in all samples. If the
median of the raw values was below 10 then
each measurement for that protein was divided
by 10. This normalisation procedure must used
to calculate the standard correlation of all
samples.
– Normalisation to control samples: Values below
0.01 were set to 0.01. Each measurement was
divided by the 50.0th percentile of all measure-
ments in that sample. Treated samples must
normalise against the medium of samples of the
same time point. Each measurement for each
biomarker protein in those specific samples
should divide by the median of that protein’s
measurements in the corresponding control
samples. For all calculations within or in
between samples this normalisation procedure
should chosen.
Statistics
– Due to difficulties either in sample preparation,
in protein preparation or in assay or protein-
chip hybridisation the amount of replicas varied
from zero to six. Thus implicating different
optimal statistical tests were necessary for the
various settings.
Filter by Control Strength
– Control strength (CS) is a synthetic control value
that resulted from the normalisation steps. In
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common case, it is equal to the median of the per
assay normalised expression values of the control
samples. Measurements with higher control
strength are relatively more precise than measure-
ments with lower control strength. If all control
strength values are plotted against the standard
deviation of the normalised value, the best cut off
to filter data is where the curve flattens out (where
the measurement for the data becomes more
reliable).
Log transformation
– Log transformation can minimise the impact of
outliers with high signals (essentially they make
non-normal distributions look more normal-like).
Data should be interpreted in log of ratio mode
because parametric tests assume that means of the
population under study are normally distributed
(Gaussian distribution). All statistical tests must
apply to the distribution of natural logs of the
ratios for each protein.
One sample t-test
– The one sample t-test, determines the likelihood if
the average ratio in the log replicates interpretation
is significantly different from 1.0. A filter (Pÿ.05)
will be applied to the P values to determine the
statistical significance of each protein’s differential
expression.
1-way ANOVA
– One-way analysis of variance (ANOVA) tests
allow determining if, in our case treatment of
patient with drugs, has a significant effect on
protein expression behavior across the groups
untreated and treated at a specific time point. A
Welch t-test (variances assumed not to be equal)
using GEM variances with p ÿ 0.05 should be
performed. It will be not possible to apply this
approach to the comparison of all samples, due to
its stringency.
MTC: Multiple Testing Corrections
– To avoid type 1 error (false positives) which
occurs when the biomarker/analyte is not differen-
tially expressed and the analysis concludes that
this is significant, Benjamini and Hochberg False
Discovery Rate should used. The purpose of a
multiple testing correction is to keep the overall
error rate/false positives to less than the user
specified p-value cutoff, even if several bio-
markers/analytes are being analysed. In datasets,
where samples from different cohorts were com-
pared, no MTC could be applied because it will be
too restrictive.
Sample Specificity
– Before starting the analysis, the samples should
checked for quality by measuring their similarities
within a given samples cohort. The “Find Similar
Samples” allows running a comparison between a
target sample and a specified group of samples.
The algorithm uses a Spearman correlation, which
takes the relative ranks of the raw expression
values (as opposed to the normalised values).
Protein Ontology Classification
– Ontology comprises a set of well-defined terms
with well-defined relationships. The structure itself
reflects the current representation of (biological)
knowledge as well as serving as a guide for
organising new data.
– Out of the three described classifications (molec-
ular function, process and subcellular location) we
will chose molecular function to classify our
proteins. Molecular function is defined as the
biochemical activity (including specific binding
to ligands or structures) of a protein product. This
definition also applies to the capability that a
protein product (or protein product complex)
carries as a potential [12].
Recommendations and outlook
Immunoassays are applied in such important areas as the
quantitation of biomarker molecules in prospective
medicine which indicate disease progression or regres-
sion, and antibodies elicited in response to treatment with
therapeutic drug candidates. Currently available guidance
documents dealing with the validation of bioanalytical
methods address immunoassays in only a limited way. In
the course of our review we present recommendations for
specific aspects of immunoassay characterisation and
validation. Immunoassay calibration curves are inherently
nonlinear, and require nonlinear curve fitting algorithms
for best description of laboratory data. Demonstration of
specificity of the immunoassay for the analyte or
biomarker of interest is critical because most immuno-
assays are not preceded by extraction of the analyte from
the matrix of interest. Since the core of the assay is an
antigen-antibody reaction, immunoassays may be less
precise and less specific leading sometime to false
positive results. Criteria for accuracy (mean bias) and
precision, both in pre-study validation experiments, and in
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the analysis of in-study quality control samples, should be
more lenient than for other assay. Our recommendations for
immunoassay validation are presented in the hope that their
consideration may result in the production of consistently
higher quality data from the application of these methods in
predictive, preventive and personalised medicine.
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